Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models-Reference-Cited by-同舟云学术

Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models

Published:2024-01-25 Issue:3 Volume:67 Page:2188-2201
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Privat Malorie¹²³,Massot Aurélie¹²,Hermetet François⁴⁵,Al Sabea Hassan³,Racoeur Cindy¹²,Mabrouk Nesrine¹²,Cordonnier Marine⁴,Moreau Mathieu³,Collin Bertrand³⁶,Bettaieb Ali¹²,Denat Franck³^ORCID,Bodio Ewen³^ORCID,Bellaye Pierre-Simon⁶,Goze Christine³^ORCID,Paul Catherine¹²^ORCID

Affiliation:

1. LIIC, EA7269, Université de Bourgogne, 21000 Dijon, France

2. Laboratoire d’Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000 Paris, France

3. ICMUB, UMR 6302 CNRS, Université de Bourgogne, 9 av. A. Savary, BP 47870, 21078 Dijon, France

4. INSERM, UMR 1231, Label Ligue Nationale contre le Cancer and LipSTIC, 21000 Dijon, France

5. CRIGEN, 21000 Dijon, France

6. Centre Régional De Lutte Contre Le Cancer Georges-François Leclerc C.G.F.L, plateforme d’imagerie et de radiothérapie précliniques, 21000, Dijon, France

Funder

Agence Nationale de la Recherche

European Regional Development Fund

Universit? de Bourgogne

Minist?re de l'Enseignement Sup?rieur et de la Recherche Scientifique

Ligue Contre le Cancer

Centre National de la Recherche Scientifique

Conseil r?gional de Bourgogne-Franche-Comt?

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02120

Reference44 articles.

1. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

2. Immune checkpoint inhibitors: recent progress and potential biomarkers

3. The blockade of immune checkpoints in cancer immunotherapy

4. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis